Adagen market seen growing to $0.13 million by 2030

The Business Research Company says the global Adagen market is set for steady growth, rising from $0.09 million in 2025 to $0.1 million in 2026 and reaching $0.13 million by 2030. The report points to rising precision medicine use, more rare disease diagnoses and higher healthcare spending as key drivers, with North America leading and Asia-Pacific expected to grow fastest.

Why it matters: - Adagen serves a small but critical patient population with severe combined immunodeficiency caused by adenosine deaminase deficiency. - The market’s growth reflects broader demand for rare disease therapies, precision medicine and specialized immunology care. - The forecast points to continued investment in orphan drugs and pediatric rare disease treatment.

What happened: - The Business Research Company released its Adagen Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report estimates the Adagen market will rise from $0.09 million in 2025 to $0.1 million in 2026. - The report projects the market will reach $0.13 million by 2030. - The report places North America as the largest regional market in 2025. - The report expects Asia-Pacific to be the fastest-growing region during the forecast period. - The report covers Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot graphics, and updated charts and tables. - The report offers a free sample and the full report.

The details: - Adagen is the brand name for pegademase bovine. - Adagen is an enzyme replacement therapy for SCID caused by ADA deficiency. - The treatment works by replenishing the missing enzyme needed for immune system development. - The therapy helps reduce the risk of life-threatening infections in affected patients. - Historical growth has been supported by the lack of alternative therapies for ADA SCID, early enzyme replacement therapy success, improved patient survival, orphan drug incentives and use by specialized immunology centers. - The market’s forecast growth is supported by genetic screening advances, rising rare disease awareness, more specialty immunology clinics, favorable reimbursement policies and higher investment in orphan drug development. - Expected trends include continued enzyme replacement therapy use, long-term SCID management, supportive immunology care and more focus on pediatric rare disease treatment.

Between the lines: - Precision medicine is becoming a stronger driver because Adagen is a targeted therapy tailored to a specific genetic disorder. - The report cites Personalized Medicine Coalition data showing the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - Rising rare disease diagnosis rates are expanding the patient pool that can be identified and treated earlier. - Genetic Alliance UK reported in February 2024 that rare conditions affect over 3.5 million people in the UK, and 1 in 17 people will experience a rare disease in their lifetime. - The same data said 70% of rare conditions affect children and more than 30% of affected children die before age five. - Higher healthcare spending is also supporting demand for specialized treatment and care infrastructure. - The UK Office for National Statistics reported a 5.6% rise in healthcare spending from 2022 to 2023, reaching about $317.63 billion in 2023.

What’s next: - The market’s growth path will likely depend on broader rare disease screening, reimbursement support and continued orphan drug development. - Regional expansion appears strongest in Asia-Pacific as healthcare systems improve and awareness rises. - The report points to sustained use of Adagen in specialized centers rather than broad mainstream adoption.

The bottom line: - Adagen remains a niche market, but the combination of precision medicine, rare disease detection and healthcare spending is expected to keep demand growing through 2030.